CMDX and Array Genomics Collaborate to Expand Diagnostic Microarray Technology
News Mar 16, 2006
Acacia Research Corporation has announced that its CombiMatrix group’s subsidiary Combimatrix Molecular Diagnostics (CMDX) and Array Genomics Inc. will co-develop, market, and sell an exciting series of comparative genomic hybridization (CGH) microarray products and services internationally, using expertise and technology from both companies.
The initial products, which will be manufactured in the U.S. by CMDX and distributed in Europe by AG, are a series of arrays for the diagnosis of mental retardation anomalies.
It is anticipated that the arrays will begin generating revenue for both companies within the next several weeks.
Array-based CGH is an analytical approach, which utilizes an ordered set of human DNA clones in a microarray format to detect unbalanced chromosome rearrangements associated with both constitutional and acquired genetic maladies and syndromes.
When compared to conventional cytogenetic approaches, array-based CGH reduces the time associated with the clinical analysis and detection of chromosomal imbalances, while increasing the resolution of detection.
"Over the last several years we have been highly involved with emerging technologies in the clinical cytogenetics arena, and in particular with array-based CGH initiatives," said Mr. Ian Jones, General Manager of Array Genomics.
"We are excited to be able to work with CMDX’s high performance CGH array platform to enhance the quality of the technology to our customers."
"CMDX is positioning itself to become a leader in the burgeoning molecular diagnostics marketplace," stated Matt Watson, CEO of CMDX.
"In addition to selling our CGH products in Europe and other countries abroad, we intend to begin offering molecular diagnostic testing services at our Irvine, CA - based clinical laboratory."
"These tests will be run as laboratory developed tests, also known as the ‘Home Brew’ tests, and will primarily be based on CGH and gene expression profiling (GEP) technologies."
"We also intend to file a number of our proprietary tests with the FDA for approval to market them within the U.S. as IVD products."
"We are pleased to be able to offer these and future products and services to the market after only 9 months in business and we look forward to expanding our technology base and increasing our sales going forward."
"We are pleased to be expanding our capabilities in Array CGH, which is very complimentary to our CustomArrays," said Dr. Amit Kumar, President and CEO of CombiMatrix.
"We also are pleased to be expanding the scope of our business to include mental retardation in addition to our cancer focus. We anticipate that we will continue to expand into other disease areas."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.